Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$0.25 - $2.24 $20,038 - $179,542
80,153 Added 129.22%
142,183 $42,000
Q2 2022

Aug 15, 2022

SELL
$1.72 - $2.51 $169,705 - $247,651
-98,666 Reduced 61.4%
62,030 $129,000
Q1 2022

May 16, 2022

SELL
$1.72 - $2.47 $131,733 - $189,174
-76,589 Reduced 32.28%
160,696 $386,000
Q4 2021

Feb 14, 2022

SELL
$1.69 - $2.31 $241,291 - $329,812
-142,776 Reduced 37.57%
237,285 $494,000
Q3 2021

Nov 15, 2021

SELL
$1.22 - $2.2 $149,146 - $268,952
-122,251 Reduced 24.34%
380,061 $730,000
Q2 2021

Aug 16, 2021

SELL
$2.06 - $2.67 $112,758 - $146,147
-54,737 Reduced 9.83%
502,312 $1.12 Million
Q1 2021

May 17, 2021

BUY
$2.49 - $6.23 $717,911 - $1.8 Million
288,318 Added 107.29%
557,049 $1.42 Million
Q4 2020

Feb 16, 2021

BUY
$3.48 - $6.47 $421,542 - $783,730
121,133 Added 82.07%
268,731 $1.74 Million
Q3 2020

Nov 16, 2020

BUY
$3.16 - $4.36 $466,409 - $643,527
147,598 New
147,598 $598,000
Q2 2020

Aug 14, 2020

SELL
$1.87 - $3.84 $51,870 - $106,513
-27,738 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$1.58 - $4.06 $5,689 - $14,620
-3,601 Reduced 11.49%
27,738 $55,000
Q4 2019

Feb 14, 2020

SELL
$2.13 - $3.83 $34,301 - $61,678
-16,104 Reduced 33.94%
31,339 $120,000
Q3 2019

Nov 14, 2019

SELL
$2.12 - $2.86 $36,553 - $49,312
-17,242 Reduced 26.66%
47,443 $113,000
Q2 2019

Aug 14, 2019

SELL
$2.35 - $3.09 $10,575 - $13,905
-4,500 Reduced 6.5%
64,685 $178,000
Q1 2019

May 15, 2019

SELL
$1.8 - $2.97 $4,640 - $7,656
-2,578 Reduced 3.59%
69,185 $182,000
Q4 2018

Feb 14, 2019

SELL
$1.51 - $2.93 $7,033 - $13,647
-4,658 Reduced 6.1%
71,763 $133,000
Q3 2018

Nov 14, 2018

BUY
$2.6 - $3.95 $198,694 - $301,862
76,421 New
76,421 $210,000
Q2 2018

Aug 14, 2018

BUY
$3.7 - $4.75 $212,750 - $273,125
57,500 New
57,500 $221,000
Q4 2017

Feb 14, 2018

SELL
$2.8 - $5.55 $50,400 - $99,900
-18,000 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$3.2 - $20.8 $57,600 - $374,400
18,000
18,000 $59,000

About OTONOMY, INC.


  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.